Jaminon, Armand M. G.
Dai, Lu
Qureshi, Abdul Rashid
Evenepoel, Pieter
Ripsweden, Jonaz
Söderberg, Magnus
Witasp, Anna
Olauson, Hannes
Schurgers, Leon J.
Stenvinkel, Peter
Article History
Received: 21 October 2019
Accepted: 17 March 2020
First Online: 20 April 2020
Competing interests
: Dr. Schurgers reports consultancy fee from Immunodiagnostic systems (IDS), outside the submitted work and grants from NattoPharma outside the submitted work; Dr. Evenepoel reports personal fees from Vifor FMC, personal fees from Amgen, personal fees from Medice, grants from Sanofi outside the submitted work. Dr. Stenvinkel reports personal fees from Astellas, grants and personal fees from Astra Zeneca, personal fees from Reata, personal fees from Corvidia, personal fees from Baxter, personal fees from Pfizer, outside the submitted work. All other authors don’t have competing interests.